Health Products and Food Branch Inspectorate
|
|
- Alice Haynes
- 6 years ago
- Views:
Transcription
1 Our Mandate: To manage and deliver a national compliance and enforcement program for blood and donor semen; cells, tissues and organs; drugs (human and veterinary); medical devices and natural health products, collaborating with and across, all regions. Health Products and Food Branch Inspectorate Blood Establishment Licence Application: Forms and Instructions FRM-0354 Date issued: October 17, 2014 Date of implementation: October 23, 2014 Disclaimer: This document does not constitute part of the Food and Drugs Act (Act) or its associated Regulations and in the event of any inconsistency or conflict between that Act or Regulations and this document, the Act or the Regulations take precedence. This document is an administrative document that is intended to facilitate compliance by the regulated party with the Act, the Regulations and the applicable administrative policies.
2 INTRODUCTION This application form is intended for blood establishments to use when: - Applying for a Blood Establishment Licence (BEL) - Amending a BEL - Submitting administrative changes - Submitting other supporting documents associated to a BEL - Cancelling a BEL Guidance on submission requirements for these various application types can be found in the Blood Establishment Licence (BEL) Application Checklist. GENERAL INSTRUCTIONS PART A: ESTABLISHMENT INFORMATION In this section, Establishment Name refers to the legal name of the establishment to which the BEL is/will be issued. The address in this section should refer to the head office of the establishment (not necessarily where the activities are being conducted). PART B: ATTESTATION SIGNATURE This section is to be completed by a Senior Executive Officer upon every application. PART C: CANADIANBUILDING INFORMATION and PART D: OTHER ESTABLISHMENT INFORMATION The building(s) of the applying establishment, in which the activities are conducted in Canada, are identified in PART C: CANADIAN BUILDING INFORMATION. If some or all of the activities are done by another establishment either domestic and/or foreign, on behalf of the applying establishment, this Other Establishment information should be entered in PART D: OTHER ESTABLISHMENT INFORMATION. If activities are being conducted in more than 1 building, copy and paste the Part C and/or Part D template as many times as required to enter additional buildings, and/or other establishments, respectively. Additional information/clarification can be provided within the cover letter. As per the definitions provided, check all components in respect of which activities are proposed to be conducted. Do not fill in the shaded areas. ** Other Activity and Other Component can only be included if previously cleared with Health Canada by contacting blood_sang_questions@hc-sc.gc.ca. Activity Definitions: Allogeneic: In respect of blood or a blood donation, means that the blood is collected from an individual either for transfusion into another individual or for use in the manufacture of a drug for human use. Designated donation: Means a blood donation that is made by a donor who is selected for medical reasons to make the donation for a specific recipient. Directed donation: Means a blood donation that is made by a donor who is known by the recipient and selected for medical reasons by the recipient s physician. Blood Establishment Licence Application: Form and Instructions (FRM-0354) /October 17, 2014 Page 2 of 10
3 A. Donor suitability assessment: Means an evaluation of a donor that is based on all of the following criteria: (a) the donor s medical history; (b) the results of any donor tests and physical examination; and (c) the donor s social history, to the extent that it is relevant in determining the presence of risk factors for diseases transmissible by blood. Donor tests: As per the establishment s authorization, may include measurement for hemoglobin/hematocrit, serum protein, blood pressure, temperature and weight. B. Collection: Refers to collection of whole blood for transfusion or for use in the manufacture of a drug for human use. C. Collection by Apheresis: Refers to the process of withdrawing blood from a donor, separating specific blood components from the blood and returning the remaining blood components to the donor. This procedure may be performed manually or by automated methods. D. Component Preparation: Any activity performed following the collection of blood up to and including the determination of safety. This includes, but is not limited to end labelling and storage. E. Testing: For allogeneic donations, in accordance with the establishment s authorization, testing may include: ABO/Rh Transmissible disease Clinically significant red cell antibodies Bacteriological (platelets) F. Importing: Refers to the importation of blood for transfusion from outside Canada. Note: Importation does not include blood that is of a rare phenotype not available in Canada and that is imported in accordance with a prescription. F. Distribution: Distribute does not include to transfuse. For example, distribution occurs when establishments send blood to another establishment or when the transfusion medicine laboratory sends blood to the operating theatre or the ward. G. Quality Control Testing: For allogeneic donations, in accordance with the establishment s authorization, the routine testing of blood to ensure that specifications are met. Component Definitions: 1. Whole Blood: Unaltered, anticoagulated blood collected from a donor. 2. & 9. Red Blood Cells: A blood component containing red cells concentrated through the removal of most of the plasma by sedimentation, centrifugation, or cytapheresis of whole blood. 3. Cryoprecipitate: A plasma component produced from frozen plasma and containing a specified amount of fibrinogen or a plasma component prepared from fresh frozen plasma and containing specified amounts of factor VIII and fibrinogen. 4. & 10. Platelets: A blood component consisting of a suspension of platelets in plasma or an approved storage solution, prepared by centrifugation of whole blood or by plateletpheresis. 5. Platelets Pooled Pre-Storage: Whole blood derived platelet units that are pooled prior to storage and determined safe for distribution. Note: this is in contrast to platelet units that are pooled after being placed in storage and prior to transfusion. 6. Cryosupernatant Plasma: Plasma from which the cold-insoluble precipitate has been removed. Blood Establishment Licence Application: Form and Instructions (FRM-0354) /October 17, 2014 Page 3 of 10
4 7. & 13. Plasma For Further Manufacture: Plasma derived from a single donation of whole blood or plasma collected by plasmapheresis that is intended for use in producing a drug for human use, known as recovered plasma and source plasma, respectively. 8. Blood Samples for Testing: Samples of blood collected for testing, such as ABO/Rh, transmissible disease and clinically significant red cell antibodies. 11. Granulocytes: A suspension of granulocytes in plasma prepared by apheresis or prepared manually from whole blood. 12. Fresh Frozen Plasma: Plasma separated from the blood of an individual donor or collected by apheresis and placed at 18 C within 8 h of collection from the donor. 14. Frozen Plasma: Plasma separated from the blood of an individual donor or collected by apheresis and placed at 18 C within 24 h of collection from the donor. Examples of registration scenarios: 1. A contracted domestic testing laboratory (applicant) conducting testing on blood samples as per authorization for ABO/Rh, transmissible disease and clinically significant red cell antibodies would check off 8:E in Part C. 2. An establishment (applicant) processing (donor suitability assessment, collection, component preparation and testing) red blood cells from whole blood and conducting quality control testing of red blood cells as per authorization would check off 1:A, 1:B, 2:D, 2:G, and 8:E in Part C. 3. An establishment (applicant) processing (donor suitability assessment, collection, component preparation and testing) red blood cells collected by apheresis and conducting quality control testing of red blood cells as per authorization would check off 9:A, 9:C, 9:D, 9:G and 8:E: in Part C. 4. An establishment (applicant) contracting out transmissible disease testing to a foreign testing laboratory would fill out the foreign establishment s information and check off 8:E in Part D. 5. An establishment (applicant) that imports red blood cells processed (donor suitability assessment, collection, component preparation and testing) by a foreign establishment from whole blood, would check off 2:F in Part C, and in Part D, would fill out the foreign establishment s information and check off 1:A, 1:B, 2:D, 8:E and 2:F. EVIDENCE TO DEMONSTRATE COMPLIANCE OF FOREIGN ESTABLISHMENTS Please refer to Section 18(1)(k) of the Blood Regulations and Pages of the Blood Regulations Guidance document. The applicant must provide sufficient evidence to demonstrate that the foreign establishments meet the requirements of the Blood Regulations. If approved, these foreign establishment(s) will then be listed on the BEL of the establishment in Canada. Sufficient evidence includes, but is not limited to, the following information: - a list specifying the activities conducted at each building of that foreign establishment; - a certificate from a Health Canada Inspector; or - in the absence of a certificate from a Health Canada Inspector, the following documentation demonstrating that the foreign establishment meets the requirements of the Blood Regulations must be filed: a. The most recent (within the last 3 years) signed inspection report issued by i. a regulatory authority with which Canada has a Mutual Recognition Agreement e.g. Therapeutic Goods Administration (Australia), or ii. an authority which is a member of the Pharmaceutical Inspection Cooperation/Scheme [PIC/S]), e.g. United States Food and Drug Administration; b. The corrective actions taken, if any, signed by a responsible official of the foreign establishment; c. A copy of the foreign establishment s procedures for handling deviations and out of specification test results; d. A copy of the quality agreement between the foreign establishment and the Canadian establishment including a list of the specific blood and blood components for supply in Canada; Blood Establishment Licence Application: Form and Instructions (FRM-0354) /October 17, 2014 Page 4 of 10
5 e. The Site Master File or equivalent document. It is recognized that in some cases certain documentation may not exist. In such cases, a written justification explaining why the required documents cannot be filed should be provided to the Inspectorate, along with other documentation that encompasses the required information. Note: If these documents are not provided in their entirety, the application will be considered incomplete and will be screened out. APPENDIX 1: ADDITIONAL INFORMATION This section is optional; completing it will help facilitate the inspection process. Blood inventory in this section, is defined as blood that is already determined safe for distribution (i.e. released inventory). ADDITIONAL TOOLS For a copy of Frequently Asked Questions (FAQ) regarding establishment licences and registrations under the Blood Regulations Please contact blood_sang_questions@hc-sc.gc.ca Additional information can be found within the Guidance Document: Blood Regulations: ADDITIONAL QUESTIONS ABOUT BLOOD ESTABLISHMENT LICENSING? Please send your inquiries to: blood_sang_questions@hc-sc.gc.ca READY TO SUBMIT? 1. Prepare an with Blood Establishment Licence (BEL) in the subject line of the and attach the completed BEL application to accelerate the triage of your application. 2. Send the with the form to: ELapplicationLE@hc-sc.gc.ca 3. You will receive an automatic reply acknowledging receipt of the sent. Please maintain records of submitting the application as well as the automatic receipt issued by our systems. Blood Establishment Licence Application: Form and Instructions (FRM-0354) /October 17, 2014 Page 5 of 10
6 BLOOD ESTABLISHMENT LICENCE (BEL) APPLICATION CHECKLIST (to be submitted with your application) APPLICATION TYPE New Application [Regulatory Reference: section 17 & 18] Administrative Changes (affecting Part A and/or B) (to be submitted as soon as possible) [Regulatory Reference: section 23 (a)] Cessation of Licensed Activities (affecting Part C and/or D) (to be submitted within 30 days after the cessation of any licensed activity) [Regulatory Reference: section 23 (b)] Amendment (affecting Part C and/or D) (licence to be amended before making the change(s)) [Regulatory Reference: section 22] Evidence to Demonstrate Compliance of Foreign Establishments [Regulatory Reference: section 18 (1) (j)] Cancellation (to be submitted within 30 days after the cessation of all licensed activities) TO BE COMPLETED Copy of Authorization (if available; except for testing under a pre-assessed donor program) Cover letter (recommended) Entire Application (where applicable) Appendix 1 Compliance information (if applicable) Cover letter (recommended) Part A Part B Cover letter (recommended) Part A Part B Revised Part C and/or D reflecting the removed activities Copy of revised Authorization (if available; except for testing under a pre-assessed donor program) Cover letter (recommended) Part A Part B Revised Part C and/or D reflecting the activities to be maintained as well as the changes Compliance information (if applicable) Cover letter (recommended) Part A Part B Part D Compliance information (if applicable) Part A Part B [Regulatory Reference: section 29] Please put Blood Establishment Licence or BEL in the subject line of the and submit the completed BEL application form, along with supporting documents (if applicable), to: ELapplicationLE@hc-sc.gc.ca Blood Establishment Licence Application: Form and Instructions (FRM-0354) /October 17, 2014 Page 6 of 10
7 BLOOD ESTABLISHMENT LICENCE (BEL) APPLICATION FORM PART A: ESTABLISHMENT INFORMATION Blood Establishment Licence # (if applicable): Application Tracking # (for internal use only): Establishment Name: Previous Name of Establishment (if applicable): Establishment Civic Address Building Name (if applicable): Street Number: Street Name: Suite: City: Province: Postal Code: Postal Address (where correspondence is to be sent) same as above Street Number: Street Name: Suite: Post Office Box: City: Province: Postal Code: Contact Information (for correspondence regarding the application) Contact Person and Title: Language: English French Telephone: Fax: Emergency Contact Person (24/7 or outside business hours) Contact Person and Title: same as above Language: English French Telephone: Fax: PART B: ATTESTATION SIGNATURE (to be completed by a Senior Executive Officer) In accordance with Section 18(1), the information provided in this application is accurate and complete. This Blood Establishment has sufficient evidence to demonstrate that it can conduct its activities in accordance with its quality management system and the requirements of the Blood Regulations and that its activities will not compromise human safety or the safety of blood. Name of Senior Executive Officer: Title: Signature: Date (yyyy-mm-dd): Blood Establishment Licence Application: Form and Instructions (FRM-0354) /October 17, 2014 Page 7 of 10
8 PART C: CANADIAN BUILDING INFORMATION (where activities are being conducted) Building Name (if applicable): Building Letter (assigned by Health Canada): Address Information same as Establishment Address (Part A) same as Postal Address (Part A) Street Number: Street Name: Suite: City: Province: Country: Canada Postal Code: Records Storage Address same as above same as Establishment Address (Part A) Street Number: Street Name: Suite: City: Province: Country: Canada Postal Code: Activity and Component Information Activity Allogeneic, Directed and Designated **Other Activity (as applicable) A. Donor Suitability Assessment B. Collection C. Collection By Apheresis D. Component Preparation E. Testing F. Importing Component G. Quality Control Testing H: I: J: 1. Whole Blood Red Blood Cells Cryoprecipitate Platelets Platelets Pooled Pre-Storage Cryosupernatant Plasma Plasma For Further Manufacture (Whole Blood) Blood Samples For Testing Red Blood Cells (Apheresis) 10. Platelets (Apheresis) Granulocytes Fresh Frozen Plasma Plasma For Further Manufacture (Apheresis) Frozen Plasma ** Other Component (as applicable) 15: 16: ** Other Activity or Other Component can only be included if previously cleared with Health Canada by contacting Blood Establishment Licence Application: Form and Instructions (FRM-0354) /October 17, 2014 Page 8 of 10
9 PART D: OTHER ESTABLISHMENT INFORMATION (if any) Establishment Name: BEL # (if applicable): Street Number: Street Name: Suite: City: Province/state: Country: Postal/Zip Code: The above establishment is associated with the following building(s) (address or building letter): Activity and Component Information of Other Establishment (conducted on applicant s behalf) Allogeneic, Directed and Designated Activity **Other Activity (as applicable) A. Donor Suitability Assessment B. Collection C. Collection By Apheresis D. Component Preparation E. Testing Component F. Distribution G: H: I: 1. Whole Blood Red Blood Cells Cryoprecipitate Platelets Platelets Pooled Pre-Storage Cryosupernatant Plasma Plasma For Further Manufacture (Whole Blood) Blood Samples For Testing Red Blood Cells (Apheresis) Platelets (Apheresis) Granulocytes Fresh Frozen Plasma Plasma For Further Manufacture (Apheresis) Frozen Plasma ** Other Component (as applicable) 15: 16: ** Other Activity or Other Component can only be included if previously cleared with Health Canada by contacting Blood Establishment Licence Application: Form and Instructions (FRM-0354) /October 17, 2014 Page 9 of 10
10 APPENDIX 1: ADDITIONAL INFORMATION Question 1: Does your establishment have a standalone blood inventory storage facility? Yes No If yes, please provide the following information: Building name (if applicable): Street Number- Street Name: Suite: City: Province: Country: Postal Code: Question 2: Does your establishment use a contracted standalone blood inventory storage facility? Yes No If yes, please provide the following information: Name of Establishment: Previous Name of Establishment (if applicable): Street Number- Street Name: Suite: City: Province: Country: Postal Code: Blood Establishment Licence Application: Form and Instructions (FRM-0354) /October 17, 2014 Page 10 of 10
CLASS III MEDICAL DEVICE LICENCE AMENDMENT APPLICATION FORM (disponible en français)
1. NAME(S) OF DEVICE LICENCE(S) BEIN AMENDED 2. LICENCE NUMBER(S) TO BE AMENDED: (provide the latest valid licence number(s)) 3. MANUFACTURER INFORMATION (as it appears on the label) Contact Name and Title:
More informationPaul Ashford Executive Director ICCBBA
Introduction to ISBT 128 Paul Ashford Executive Director ICCBBA ICCBBA ICCBBA enhances safety for patients by managing the ISBT 128 international information standard for use in transfusion and transplantation.
More informationFDA Perspective on Plasma Quality and GMPs
FDA Perspective on Plasma Quality and GMPs Judy Ellen Ciaraldi Food and Drug Administration Division of Blood Components & Devices/OBRR/CBER IPFA/BCA Global Symposium September 23, 2014 Sacramento, California
More informationSubject: Preparation of an Application for Investigational Testing - Medical Devices
Therapeutic Products Directorate Medical Devices Bureau 2934 Baseline Road, Tower B Address Locator: 3403A Ottawa, Ontario K1A 0K9 February 22, 1999 To: Medical Devices Stakeholders Subject: Preparation
More informationISBT 128 Implementation Experience
ISBT 128 Implementation Experience U. S. Army Kendrick Memorial Blood Center and Eisenhower Army Medical Center Fort Gordon, Georgia Josie Pippert MT(ASCP) Sarah Dailey MT(ASCP) Validation Protocol Army
More informationINTERNATIONAL SPECIALIST IN BLOOD BANKING WORK EXPERIENCE DOCUMENTATION FORM (Routes 2 & 3)
PART I (TO BE COMPLETED BY APPLICANT) Applicant s Name Address Email Address PART II (MUST BE COMPLETED AND SIGNED BY LABORATORY MANAGEMENT* OR EMPLOYER IN ORDER TO BE ACCEPTABLE) SUBJECT: VERIFICATION
More informationSPECIALIST IN BLOOD BANKING WORK EXPERIENCE DOCUMENTATION FORM (Routes 2, 3, & 4)
PART I (TO BE COMPLETED BY APPLICANT) Applicant s Name Last Four Digits of Applicant s Social Security # Address Email Address Daytime Telephone Number PART II (MUST BE COMPLETED AND SIGNED BY THE IMMEDIATE
More informationLaboratory: Document Type: Original Date Adopted: Previous Document: Transfusion Services Procedure 04/01/02 TRB-9 Revision 4
Laboratory: Document Type: Original Date Adopted: Previous Document: Transfusion Services Procedure 04/01/02 TRB-9 Revision 4 Document Author: Document Owner: Acknowledgement / Required Copy Holders*:
More informationGLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE
GLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE Medical Device Product Questionnaire This questionnaire is used to collect information from vendors with regards to medical devices that fall in any of the
More informationISO INTERNATIONAL STANDARD
INTERNATIONAL STANDARD ISO 3826-3 First edition 2006-09-15 Plastics collapsible containers for human blood and blood components Part 3: Blood bag systems with integrated features Poches en plastique souple
More informationSession 7 Clinical Trial Assessment Bioequivalence Studies
L1 Session 7 Clinical Trial Assessment Bioequivalence Studies Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office
More informationDISTRIBUTION AND SUPPLY OF PLASMA DERIVED FRACTIONATED BLOOD PRODUCTS AND RECOMBINANT PRODUCTS IN NEW ZEALAND
REASON FOR CHANGE: Wholesaler s licences are now issued by the Ministry of Health rather than Medsafe; clarify the approval process for the supply of products only to authorised facilities and healthcare
More informationProfessional Corporation Application for Registration (Form 4-6C)
Chartered Professional Accountants of Ontario 69 Bloor Street East Toronto ON M4W 1B3 T. 416 962.1841 Toll free 1 800 387.0735 cpaontario.ca Professional Corporation Application for Registration (Form
More informationEUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL QUESTIONS. and ANSWERS
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, F2/SM D (2008) QUESTIONS and ANSWERS The rules governing medicinal products in the European Union VOLUME 2 NOTICE
More informationTITLE OF FELLOW (FCPA) Conferred by CPA Manitoba
Chartered Professional Accountants of Manitoba 1675-One Lombard Place Winnipeg MB CANADA R3B 0X3 T. 204 943.1538 F. 204 943.7119 CPAmb.ca May 2017 Criteria and Documentation for TITLE OF FELLOW (FCPA)
More informationStability Testing for Pre-Clinical and Early Phase Clinical Drug Products
Microrite, Inc. brings you this unique learning experience in Stability Testing for Pre-Clinical and Early Phase Clinical Drug Products; Part of Microrite s step-by-step webinar series. Stability Testing
More informationGUIDELINES FOR ISSUING AND RETURNING BLOOD COMPONENTS AND BLOOD PRODUCTS WITHIN A FACILITY
GUIDELINES FOR ISSUING AND RETURNING BLOOD COMPONENTS AND BLOOD PRODUCTS WITHIN A FACILITY 1. Policy Statement 1.1 A policy shall be in place to ensure traceability of all blood components and blood products
More informationLicense Submission Checklist for Platelets, Leukocytes Reduced Collected by Pheresis
License Submission Checklist for Platelets, Leukocytes Reduced Collected by Pheresis Purpose: To provide guidance when submitting documentation to FDA in support of a BLA or a license supplement. Definitions
More informationThis document addresses the need for a date to be clearly available on a case in a standard format.
TABLE OF CONTENTS 1. STATEMENT OF DIRECTION... 3 2. INDUSTRY OBJECTIVES... 3 3. RECOMMENDATIONS... 4 4. IMPLEMENTATION TIMELINES... 6 5. ROLES... 7 6. ACCEPTANCE... 7 APPENDIX 1: CASE DATE EXAMPLES...
More informationAUSTRALIAN MEDICAL DEVICES GUIDANCE DOCUMENT NUMBER 5. The Declaration of Conformity
AUSTRALIAN MEDICAL DEVICES GUIDANCE DOCUMENT NUMBER 5 The Declaration of Conformity 30 October 2003 DISCLAIMER This document is provided for guidance only. It should not be relied upon to address every
More informationImmunohematology Practicum Objectives - CLS 645
Clinical Laboratory Sciences Department University of Kansas Medical Center Immunohematology Practicum Objectives - CLS 645 The following objectives are to be completed by the student for successful completion
More informationPRE-QUALIFICATION FOR PROVISION OF TEAM BUILDING CONSULTANCY SERVICES TENDER NO. KPPF /HRA-B/1-A/22/17-18
PRE-QUALIFICATION FOR PROVISION OF TEAM BUILDING CONSULTANCY SERVICES TENDER NO. KPPF /HRA-B/1-A/22/17-18 (JAN 2017 DEC 2018) PRE QUALIFICATION DOCUMENT Stima Plaza, Kolobot Road, P.O. Box 1548-00600 Nairobi,
More informationSTANDARD OPERATING PROCEDURE FOR ANTIBODY IDENTIFICATION - TUBE METHOD
STANDARD OPERATING PROCEDURE FOR ANTIBODY IDENTIFICATION - TUBE METHOD TITLE: STANDARD OPERATING PROCEDURE FOR ANTIBODY IDENTIFICATION TUBE METHOD 1.0 Principle An antibody identification procedure is
More informationMedical Device Single Audit Program (MDSAP) Copyright 2014 BSI. All rights reserved.
Medical Device Single Audit Program (MDSAP) International Medical Device Regulatory Forum (IMDRF) IMDRF Management Committee (MC) regulators: Australia, Brazil, Canada, China, the European Union, Japan
More informationTRACEABILITY USER MANUAL
BT No.: 0425 Ver. 6 IRISH BLOOD TRANSFUSION SERVICE TITLE: TRACEABILITY USER MANUAL Supersedes Version: 5 Change Description: Revise BT - 0425. Update traceability user manual. In section 4.7 include re-routing
More informationSTANDARD OPERATING PROCEDURES DIVISION OF COMPARATIVE MEDICINE UNIVERSITY OF SOUTH FLORIDA
STANDARD OPERATING PROCEDURES DIVISION OF COMPARATIVE MEDICINE UNIVERSITY OF SOUTH FLORIDA SOP#: 014.5 Date Issued: 11/00 Date Revised: 8/15 Page 1 of 5 TITLE: SCOPE: RESPONSIBILITY: PURPOSE: Research
More informationCANADA (HEALTH CANADA)
1 GMP GAZETTE TM January 2016 HPFBI CANADA (HEALTH CANADA) NNHPD NHPs Notice to Stakeholders Regarding Site Licensing Update Who s affected? Manufacturers, packagers, labellers, importers, and distributors
More informationInvestigator-Initiated INDs
Investigator-Initiated INDs Marjorie Small, RN, CCRC Office of Clinical Research 23 May 2011 PPHS/IRB Research Grand Rounds Outline of Presentation I. What is an IND? II. Code of Federal Regulations III.
More informationCOPING WITH INCREASING NEEDS FOR INSPECTIONS: ASEAN INITIATIVES. Abida Syed M Haq Ministry of Health, Malaysia
COPING WITH INCREASING NEEDS FOR INSPECTIONS: ASEAN INITIATIVES Abida Syed M Haq Ministry of Health, Malaysia Presentation Outline About ASEAN Background Economic Integration Current Scenario Acceptable
More informationGuide to Applications for Certificates of Free Sale for Cosmetics
Guide to Applications for Certificates of Free Sale for Cosmetics AUT-G0051-6 23 FEBRUARY 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes
More informationGuidance Document. Meeting Requirements as a Registered Food Importer. A guidance document issued by the Ministry for Primary Industries
Guidance Document Meeting Requirements as a Registered Food Importer. 23 February 2016 A guidance document issued by the Ministry for Primary Industries Title Meeting Requirements as a Registered Food
More informationExcipient Albumin CSL Behring Human Serum Albumin
Excipient Albumin CSL Behring Human Serum Albumin For more information, contact CSL Behring USA: (610) 878-4000 1020 First Avenue King of Prussia, PA 19406-0901 Switzerland: +41 31 344 44 44 Wandorfstrasse
More informationRecognized Experts. Competence Area
1(4) Recognized Experts Competence Area This memo concerns the content of detailed instructions for the evaluation and approval of recognized experts in accordance with section 48, subsection 2 of the
More informationComponent Preparation, Manufacturing and Modifications
Component Preparation, Manufacturing and Modifications Mahdokht Parsi, MPH, MT(ASCP) Director of Operation, Immunohematology & Genomics Mparsi@nybc.org Current Practices in Transfusion Medicine 1 NEW YORK
More informationFAQ ABOUT. 21CFR Part 1271 FDA REGULATION OF REPRODUCTIVE TISSUE LABS
FAQ ABOUT 21CFR Part 1271 FDA REGULATION OF REPRODUCTIVE TISSUE LABS XYTEX INTERNATIONAL, LTD. AUGUSTA, GEORGIA NOVEMBER 2005 Xytex International, 2005 Xytex is a registered trademark of Xytex International,
More informationGUIDE. DWWP Amendments Licence Amendments Licence Renewals & New System Applications. Municipal Residential Drinking Water Systems
GUIDE FOR APPLYING FOR DWWP Amendments Licence Amendments Licence Renewals & New System Applications Municipal Residential Drinking Water Systems SAFE DRINKING WATER BRANCH November 2010 PIBS 7014e01 Guide
More informationThe Proposed Safe Food for Canadians Regulations (SFCR) Information Session
The Proposed Safe Food for Canadians Regulations (SFCR) Information Session 2011 Her Majesty the Queen in Right of Canada (Canadian Food Inspection Agency), all rights reserved. Use without permission
More information3. VERIFICATION OF ITEMS SUBMITTED: All documentation submitted will be verified.
Name of Applicant (please print) Date of Application INSTRUCTIONS FOR COMPLETING APPLICATION 1. APPLICATION APPROVAL: Please allow four to eight weeks for processing your application from the date of receipt
More informationNHSBT Portfolio of Blood Components and Guidance for their Clinical Use. Summary of Significant Changes. Purpose. Definitions. Applicable Documents
This Specification replaces SPN223/7 Copy Number Effective: 21/12/16 Summary of Significant Changes Introduction of HEV testing, and Pooled Platelets in Plasma/Additive mixture Amendment to interruption
More informationEU and FDA GMP Regulations: Overview and Comparison
THE QUALITY ASSURANCE JOURNAL, VOL. 2, 55 60 (1997) EU and FDA GMP Regulations: Overview and Comparison The increasing emphasis on global supply of drug products, as well as starting materials and investigational
More informationWhite paper: Code of GMP Chapter 4 Documentation - PIC/S versus EU
White paper: Code of GMP Chapter 4 Documentation - PIC/S versus EU Numerous articles are available comparing the current and previous EU Code of GMP Chapter 4: Documentation, but no comparison exists between
More informationPRE-QUALIFICATION OF SUPPLIERS PROVISION OF FUMIGATION, SANITATION AND SANITAL DISPOSAL SERVICES TENDER NO.KPLC1/5BC/9A/PT-ST/113/2010
The Kenya Power & Lighting Co. Ltd. The Kenya Power & Lighting Co. Ltd. Central Office P.O. Box 30099 Nairobi, Kenya Telephone 254-02-3201 000/3201 323 Fax No. 254-02-310336 or 3753833 Website: www.kplc.co.ke
More informationPARTNERS HUMAN RESEARCH COMMITTEE. Human Tissues: Brief Primer on Research Use and Requirement for Partners IRB Review
PARTNERS HUMAN RESEARCH COMMITTEE Human Tissues: Brief Primer on Research Use and Requirement for Partners IRB Review For the purposes of this Primer, tissue is defined as any biological specimen obtained
More informationAPPLICANT'S CHECKLIST
APPLICANT'S CHECKLIST Research tissue bank (or other research biobank) REC Ref: Title of Tissue Bank: Applicant's Name: Name of Designated Individual: Please complete this checklist and send it with your
More informationGLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE
GLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE Finished Pharmaceutical Product Questionnaire This questionnaire is used to collect information from vendors with regards to finished pharmaceutical products
More informationGuidelines. Application template Call 2018 KA1 - Learning Mobility of Individuals KA109 - Vocational Education and Training Mobility Charter.
Ref. Ares(2017)5680072-21/11/2017 DISCLAIMER This document represents a template of an application form. It must not be used for real applications to a National Agency. Please also note that the sections
More informationApplication form UNIVERSITY OF NOTTINGHAM MEDICAL SCHOOL ETHICS COMMITTEE
Application form UNIVERSITY OF NOTTINGHAM MEDICAL SCHOOL ETHICS COMMITTEE In completing this form please refer to the attached Notes of Guidance Application for approval of all studies involving Healthy
More informationWork plan for the GMP/GDP Inspectors Working Group for 2017
13 January 2017 EMA/INS/GMP/584202/2016 Work plan for the GMP/GDP Inspectors Working Group for 2017 Chairperson: David Cockburn Adopted: December 2016 1. Meetings scheduled for 2017 Face-to-face meetings
More informationmechanism. GMP certificates Belén Escribano, PhD Head of the Pharmaceutical Inspection and Enforcement Department of AEMPS
Mutual recognition: basic aspects and mechanism. GMP certificates Belén Escribano, PhD Head of the Pharmaceutical Inspection and Enforcement Department of AEMPS The EU network of medicines agencies 31
More informationAuditing Microbiology Media Suppliers
Microrite, Inc. brings you this unique learning experience in Auditing Microbiology Media Suppliers; Part of Microrite s step-by-step webinar series. Auditing Microbiology Media Suppliers More often than
More informationTo: Prefectural Governors From: Director-General, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare
Provisional Translation (as of March 2010) PFSB (Yakushoku) Notification No. 0216002 February 16, 2005 To: Prefectural Governors From: Director-General, Pharmaceutical and Food Safety Bureau, Ministry
More informationREGULATION OF BIOLOGICAL PRODUCTS IN PERU. Vicky Roxana Flores Valenzuela General Directorate of Medicines, Supplies and Drugs (DIGEMID)
REGULATION OF BIOLOGICAL PRODUCTS IN PERU Vicky Roxana Flores Valenzuela General Directorate of Medicines, Supplies and Drugs (DIGEMID) CONTENTS Introduction of DIGEMID Legal Bases of Biological Products
More informationHealth Canada Enforcement of Consumer Products
September 27, 2016 Vietnam Buyers Training Health Canada Enforcement of Consumer Products Jerry Wu Regional Manager, Consumer Product Safety Health Canada OVERVIEW Monitoring the Marketplace Inspections
More information07/30/2013. Record of Revisions IRB Page 1 of 17
Current Protocol Version 7.1 (Continuing Review) Approved July 30, 2013 Version 7.1 (Amendment) September 6, 2012 Version 7.0 (Continuing Review) July 30, 2012 Version 6.0 (Continuing Review) July 30,
More informationAnalysis & Planning Guide for Implementing the Phase IV CAQH CORE Operating Rules
Analysis & Planning Guide for Implementing the Phase IV CAQH CORE Operating Rules December 2015 Table of Contents 1. Introduction: Analysis & Planning for Phase IV CAQH CORE Operating Rule Implementation...
More informationDirector of Evaluation and Licensing Division Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare
Provisional translation (as of March 27, 2008) 1 PFSB / ELD Notification No. 0210004 February 10, 2005 *Revised in accordance with PFSB / ELD Notification No. 0619004 June 19, 2007 Director of Evaluation
More informationCFIA Food Regulatory Modernization
CFIA Food Regulatory Modernization Saskatchewan Green Trades Conference November 7, 2014 2011 Her Majesty the Queen in Right of Canada (Canadian Food Inspection Agency), all rights reserved. Use without
More informationEmployer s Guide: Applying for Approval of Excess Weekly Hours of Work and Averaging Hours of Work
Employer s Guide: Applying for Approval of Excess Weekly Hours of Work and Averaging Hours of Work These publications are provided for your information and convenience only. They are not legal documents.
More informationAgenda Item 9 CX/FICS 07/16/9 September 2007
Agenda Item 9 CX/FICS 07/16/9 September 2007 Background JOINT FAO/WHO FOOD STANDARDS PROGRAMME CODEX COMMITTEE ON FOOD IMPORT AND EXPORT INSPECTION AND CERTIFICATION SYSTEMS Sixteenth Session Surfer s
More informationQuality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits
Quality Assurance QA 601.01 STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval: Frederick
More informationSQF 2000 Code. 6th Edition AUGUST A HACCP-Based Supplier Assurance Code for the Food Manufacturing and Distributing Industries
SQF 2000 Code A HACCP-Based Supplier Assurance Code for the Food Manufacturing and Distributing Industries 6th Edition AUGUST 2008 Safe Quality Food Institute 2345 Crystal Drive, Suite 800 Arlington, VA
More informationSerological Testing: Why we did what we did!
Serological Testing: Why we did what we did! W. John Judd, FIBMS, MIBiol Emeritus Professor University of Michigan What we did Provided blood and blood products in a timely, cost-efficient manner. Implemented
More informationApplication template Call 2018
DISCLAIMER This document represents a template of an application form. It must not be used for real applications to a National Agency. Please also note that the sections and questions presented below may
More informationBIOVIGILANCE IN THE UNITED STATES: Regulatory Perspective
BIOVIGILANCE IN THE UNITED STATES: Regulatory Perspective Alan E. Williams, Ph.D. Office of Blood Research and Review Center for Biologics Evaluation and Research US Food and Drug Administration 15th International
More informationTitle: How to assess a PQS testing laboratory Table of Content
Version: 01.05 Effective date: 08/07/2004 Page: 2 of 22 Table of Content 1.0 Purpose... 3 2.0 Scope... 3 3.0 Responsibility... 3 4.0 Documentation required... 4 5.0 Procedure... 4 5.1 Assessment Register...
More informationEURASIAN ECONOMIC COMMISSION COUNCIL
EURASIAN ECONOMIC COMMISSION COUNCIL Working translation: DECISION October 9, 2014 No.94 Minsk On the Regulation on the Harmonized Procedure of Joint On-Site Inspections and of Taking Samples of Goods
More informationMEDICAL DEVICE GUIDANCE
Effective from 1 January 2013 MEDICAL DEVICE GUIDANCE GN-15: Guidance on Medical Device Product Registration Revision 5 CONTENTS 1. INTRODUCTION... 4 1.1. Scope... 5 1.2. Definitions... 5 2. RISK CLASSIFICATION
More informationChallenges In Cell Product Labeling, Tracking And Traceability
Challenges In Cell Product Labeling, Tracking And Traceability April 4-5, 2008 Columbus, Ohio Dave Krugh, MT(ASCP)SBB, CLS,CLCP(NCA) Clinical Program Manager, BMT Program Clinical Instructor, Department
More informationHow to obtain Consultative Status with ECOSOC
How to obtain Consultative Status with ECOSOC Application package: application form. appendix (summary). constitution/charter. statutes/by-laws. certificate of registration. recent financial statement.
More informationIn the huge expanse of Asia, Singapore and
New Medical Device Regulation 16 February 2009 By Ames Gross In the huge expanse of Asia, Singapore and Hong Kong are small places. However, after Japan, they are among the most advanced medical markets
More informationGuide to Scientific and Regulatory Advice for GXP activities
Guide to Scientific and Regulatory Advice for GXP activities ADV-G0019-1 7 OCTOBER 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only.
More informationIG Production and Safety
IG Production and Safety Platelet Disorder Support Association July 20, 2013 Mary Gustafson, Vice President, PPTA Global Regulatory Policy Presentation Outline Introduction - PPTA Plasma Collection Final
More informationCellular Therapy Products & NDC vs. ISBT128 Coding/Labeling
Cellular Therapy Products & NDC vs. ISBT128 Coding/Labeling William E. Janssen, Ph.D. Director, Cell Therapies Facility Moffitt Cancer Center Tampa, Florida What is ISBT 128? Information standard for blood,
More informationExpression of Interest (EOI)
Expression of Interest (EOI) Rev. July 15 2002 EOI 22021 Issued: September 16, 2002 DOCUMENT IMAGING & MANAGEMENT Insurance Corporation of British Columbia Procurement & Contract Services P210-151 West
More informationApplicability of US Regulations to Canadian Research
Applicability of US Regulations to Canadian Research Mary Kate Needler Capital District Health Authority Halifax, Nova Scotia, Canada N2 Stakeholder Meeting August 18, 2014 MK s Conventions: 1. US Regulation
More informationINDUSTRY INFORMATION SESSION Agenda
INDUSTRY INFORMATION SESSION 2012 Agenda Food Safety Enhancement Program (FSEP) update Validation of control measures HACCP system maintenance & reassessment Action plan CFIA verification of FSEP recognized
More informationMASTER FILE PROCEDURES
MASTER FILE PROCEDURES Natural Health Products Directorate August 2006 Version 1.0 Our mission is to help the people of Canada maintain and improve their health, while respecting individual choices and
More informationMONITORING AND REPORTING (ARTICLE
CBD Distr. LIMITED UNEP/CBD/NP/COP-MOP/1/L.10 16 October 2014 IGINAL: ENGLISH CONFERENCE OF THE PARTIES TO THE CONVENTION ON BIOLOGICAL DIVERSITY SERVING AS THE MEETING OF THE PARTIES TO THE NAGOYA PROTOCOL
More informationBrexit Guidance for Stakeholders Human and veterinary medicines
Brexit Guidance for Stakeholders Human and veterinary medicines DATE: 03 JANUARY 2018 V.2 This guide does not purport to be an interpretation of law and/or regulations. The content provided is subject
More informationSTANDARD OPERATING PROCEDURE FOR QUALITY CONTROL OF REAGENTS AND ANTISERA
STANDARD OPERATING PROCEDURE FOR QUALITY CONTROL OF REAGENTS AND ANTISERA TITLE: STANDARD OPERATING PROCEDURE FOR QUALITY CONTROL OF REAGENTS AND ANTISERA 1.0 Principle 1.1 The purpose of quality control
More informationAppendix B: PDMP Planning Tool
Appendix B: PDMP Planning Tool Overview In 2014, approximately 19,000 people in the United States died from overdoses of prescription opioids. Prescription drug monitoring programs (PDMPs) are a key resource
More informationLC 16 SITE PLANS, DESIGNS AND SPECIFICATIONS
Title of document ONR GUIDE LC 16 SITE PLANS, DESIGNS AND SPECIFICATIONS Document Type: Unique Document ID and Revision No: Nuclear Safety Technical Inspection Guide Date Issued: September 2015 Review
More informationAB Serum. Your Questions Answered
AB Serum Your Questions Answered Your questions answered Q: What is serum? A: Serum is the liquid part of your blood left over after the blood has clotted. It contains nutrients and factors that are needed
More informationCanada s Experience Presentation to the WCO Permanent Technical Committee March 2009
Single Window Initiative Canada s Experience Presentation to the WCO Permanent Technical Committee March 2009 Lorne Lawson Director General Border and Compliance Programs Directorate Canada Border Services
More informationTable of Contents. United Nations Verification and Inspection Mechanism for Yemen Standard Operating Procedures V2.0 Assistance
United Nations Verification and Inspection Mechanism for Yemen Standard Operating Procedures V2.0 Assistance Table of Contents Abbreviations 2 Introduction 3 Mandate 3 Aim 3 Purpose and Scope of these
More informationCUSTOMER AND SUPPLIER ROLES AND RESPONSIBILITIES FOR 21 CFR 11 COMPLIANCE ASSESSMENT. 21 CFR Part 11 FAQ. (Frequently Asked Questions)
21 CFR Part 11 FAQ (Frequently Asked Questions) Customer and Supplier Roles and Responsibilities for Assessment of METTLER TOLEDO STARe Software Version 16.00, including: - 21 CFR 11 Compliance software
More informationThe basics of funding mix. 15 days November 13 th to December 1 st 2017, course fees Choice of a donor Donor s ID card
15 days November 13 th to December 1 st 2017, course fees 2000 The basics of funding mix Choice of a donor Donor s ID card To provide participants with the critical skills required to raise funds for humanitarian
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Ref. Ares(2015)4234460-12/10/2015 Medicinal products quality, safety and efficacy Brussels, 12 October 2015 EudraLex Volume 4 EU Guidelines
More informationTrinity College Dublin QP Forum 2017 Tuesday 25 th April
Trinity College Dublin QP Forum 2017 Tuesday 25 th April HPRA QUESTIONS & ANSWERS 1. What is the approach being taken for audit of contamination control strategies as per chapters 3 & 5? What is the current
More informationBULLETIN 34: BUILDING ENVELOPE SERVICES APPROPRIATE PROFESSIONAL PRACTICE
200-4010 Regent Street Burnaby BC V5C 6N2 Canada Telephone: (604) 430-8035 Toll Free Canada-wide: 1-888-430-8035 Facsimile: (604) 430-8085 BULLETIN 34: BUILDING ENVELOPE SERVICES APPROPRIATE PROFESSIONAL
More informationPROTOCOL FOR A RESEARCH SAMPLE REPOSITORY FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, OTHER CELLULAR THERAPIES AND MARROW TOXIC INJURIES
Center for International Blood and Marrow Transplant Research PROTOCOL FOR A RESEARCH SAMPLE REPOSITORY FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, OTHER CELLULAR THERAPIES AND MARROW TOXIC
More informationMultiple Myeloma Research Foundation 2014 Research Fellow Award Program Guidelines
Multiple Myeloma Research Foundation 2014 Research Fellow Award Program Guidelines Program Description: MULTIPLE MYELOMA RESEARCH FOUNDATION 2014 RESEARCH FELLOW AWARD The Multiple Myeloma Research Foundation
More informationGuide to Wholesaling and Brokering of Medicinal Products for Human Use in Ireland
Guide to Wholesaling and Brokering of Medicinal Products for Human Use in Ireland IA-G0008-5 17 JUNE 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance
More informationREGISTRATION OF MEDICAL DEVICE. SUBMISSION & APPLICATION By IDAMAZURA IDRIS MEDICAL DEVICE AUTHORITY
REGISTRATION OF MEDICAL DEVICE SUBMISSION & APPLICATION By IDAMAZURA IDRIS MEDICAL DEVICE AUTHORITY Medical device: regulated item under the Medical Device Act 2012 (Act 737) and its regulation The objective:
More informationOne One Ton Regular Cab 4x4 2 Door Truck Transportation, Infrastructure & Energy
Department of Finance Procurement Services REQUEST FOR QUOTATION Tender Number: 4831 Closing Date: 29-Aug-2017 Closing Time: 12:00PM One One Ton Regular Cab 4x4 2 Door Truck Transportation, Infrastructure
More informationBiological Qualifier An INN Proposal. Programme on International Nonproprietary Names (INN)
INN Working Doc. 14.342 Rev. Final October 2015 Distr.: UNRESTRICTED ENGLISH ONLY Biological Qualifier An INN Proposal Programme on International Nonproprietary Names (INN) Technologies Standards and Norms
More informationNATO MUTUAL GOVERNMENT QUALITY ASSURANCE (GQA) PROCESS
AQAP 2070 NATO MUTUAL GOVERNMENT QUALITY ASSURANCE (GQA) PROCESS AQAP 2070 (January 2004) I ORIGINAL Page blank II ORIGINAL AQAP 2070 NORTH ATLANTIC TREATY ORGANIZATION NATO STANDARDISATION AGENCY (NSA)
More informationREGISTRATION FOR SUPPLY, DELIVERY, INSTALLATION, REPAIR AND MAINTENANCE OF AIR CONDITIONERS SERVICE PROVIDERS
UNIVERSITY OF EMBU REGISTRATION FOR SUPPLY, DELIVERY, INSTALLATION, REPAIR AND MAINTENANCE OF AIR CONDITIONERS SERVICE PROVIDERS UoEm/04/2017-2019 CLOSING DATE: APRIL 18TH 2017 AT 11.00 AM Table of Contents
More information